IP-6 Inositol Topical Composition for Fast Raynaud's Vasodilation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Raynaud's syndrome, peripheral neuropathy, and erectile dysfunction face challenges such as difficulty in obtaining medications, long time to reach clinical effect, skin irritation, and ease of use issues with existing transdermal agents like topical nitroglycerin.
Innovation Solution
A transdermal topical cream or ointment comprising IP-6, inositol, and colloidal oatmeal, with IP-6 acting as a carrier to deliver these ingredients into the dermis, providing quick-acting and long-lasting relief by relaxing nerve endings and promoting vasodilation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical nitroglycerin is used to treat Raynaud's syndrome, then vasodilation effect is achieved, but skin irritation occurs and application complexity increases
Solution Approach 1:
The patent uses IP-6 (inositol hexaphosphate) as a carrier substance that mediates the delivery of inositol to the affected areas. IP-6 acts as an intermediary that reduces skin irritation while enabling effective transdermal delivery of the active ingredient inositol, thus resolving the contradiction between achieving vasodilation and avoiding skin irritation
Solution Approach 2:
The patent changes the chemical parameters by using inositol and its salt forms (particularly IP-6) instead of nitroglycerin. This parameter change in the chemical substance leads to different pharmacological properties that achieve vasodilation through a different mechanism (nerve ending relaxation rather than direct vascular smooth muscle relaxation), thereby avoiding the skin irritation associated with nitroglycerin
2Reliability
If topical nitroglycerin is applied, then vasodilation is achieved, but application procedure complexity increases due to rotation sites and prevention of rubbing
Solution Approach 1:
The patent extracts and eliminates the problematic constraints associated with nitroglycerin application. By using inositol/IP-6 in a cream or ointment base, the invention removes the need for site rotation and the requirement to prevent rubbing, simplifying the application procedure while maintaining therapeutic effectiveness
Solution Approach 2:
The composition is formulated to be self-sufficient and easy to apply without special precautions. The cream or ointment base with inositol and IP-6 can be directly applied and rubbed into the affected areas without needing to be covered or rotated, making the application process simple and user-friendly
3Reliability
If topical nitroglycerin is used, then vasodilation is achieved, but time to onset of action is delayed (9-11 minutes)
Solution Approach 1:
The patent changes the chemical and physical parameters of the formulation by using inositol with IP-6 as a carrier in a cream or ointment base. This parameter change enables faster transdermal penetration and quicker onset of action compared to nitroglycerin, while achieving the same therapeutic goal of vasodilation through nerve ending relaxation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves fast-acting and soothing effects, reducing nerve ending intensity, widening blood vessels, and relaxing nerve endings to alleviate symptoms of Raynaud's syndrome, peripheral neuropathy, and erectile dysfunction without skin irritation, with a clinical effect within 5-30 minutes and lasting up to 24 hours.
Implementation Method 1
IP-6 acting as a carrier to deliver these ingredients into the dermis
Implementation Method 2
relaxing nerve endings and promoting vasodilation
Data Source
AI summary
The invention is implemented into the category of transdermal topical agents for use in regulating the dilation of blood vessels. The IP-6, Inositol, and colloidal oatmeal Nerve Relaxing Transdermal Topical Cream, Gel, or Ointment for Raynaud's Syndrome is the first topical cream containing any or all of the following: IP-6, inositol, and colloidal oatmeal, with IP-6 as the carrier agent. The present invention will allow for the decrease in the time to full clinical effect, eliminate having to wear a patch of paper over the application site, and eliminate the problem of skin irritation due to the IP-6 delivering the colloidal oatmeal to the application area to provide extra soothing and moisturizing properties. The present invention is specifically and uniquely designed for ease of use and quick action of full clinical effect with the relaxation of nerve endings that lead to dilation of extremely constricted blood vessels in mind.